Literature DB >> 19343353

[Functional glaucoma diagnosis].

C Erb1, K Göbel.   

Abstract

Achromatic perimetry is the gold standard in glaucoma diagnosis for detecting functional defects from glaucomatous optic neuropathy. Because achromatic perimetry is only able to detect scotomas after loss of up to 30-40% of retinal ganglion cells, early diagnosis using this method is rarely possible. Therefore, a lot of new perimetric procedures have been developed in recent years to detect new scotomas at a very early stage. This review summarizes the theoretical background of retinal ganglion cells in order to better understand the theoretical approaches of new perimetric methods. In addition, the most important commercial perimetric devices currently available are presented.

Entities:  

Mesh:

Year:  2009        PMID: 19343353     DOI: 10.1007/s00347-008-1817-9

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  77 in total

1.  Automated flicker perimetry in glaucoma using Octopus 311: a comparative study with the Humphrey Matrix.

Authors:  Chota Matsumoto; Sonoko Takada; Sachiko Okuyama; Eiko Arimura; Shigeki Hashimoto; Yoshikazu Shimomura
Journal:  Acta Ophthalmol Scand       Date:  2006-04

2.  [Comparison of frequency doubling technology perimetry and achromatic standard automated perimetry in patients with migraine without aura and controls].

Authors:  K Göbel; M Boyraz; A Schröder; C Erb
Journal:  Klin Monbl Augenheilkd       Date:  2008-08       Impact factor: 0.700

3.  The learning effect in visual field testing of healthy subjects using frequency doubling technology.

Authors:  Amjad Horani; Shahar Frenkel; Claudia Yahalom; Marilyn D Farber; Uriel Ticho; Eytan Z Blumenthal
Journal:  J Glaucoma       Date:  2002-12       Impact factor: 2.503

4.  Psychophysical investigation of ganglion cell loss in early glaucoma.

Authors:  Paul G D Spry; Chris A Johnson; Steven L Mansberger; George A Cioffi
Journal:  J Glaucoma       Date:  2005-02       Impact factor: 2.503

5.  Short-wavelength automated perimetry in patients with migraine.

Authors:  Ozlem Yenice; Ahmet Temel; Burçin Incili; Neşe Tuncer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-09-21       Impact factor: 3.117

6.  Number of ganglion cells in glaucoma eyes compared with threshold visual field tests in the same persons.

Authors:  L A Kerrigan-Baumrind; H A Quigley; M E Pease; D F Kerrigan; R S Mitchell
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-03       Impact factor: 4.799

7.  Clinical evaluation of frequency doubling technology perimetry using the Humphrey Matrix 24-2 threshold strategy.

Authors:  P G D Spry; H M Hussin; J M Sparrow
Journal:  Br J Ophthalmol       Date:  2005-08       Impact factor: 4.638

8.  Detection of optic neuropathy in glaucomatous eyes with normal standard visual fields using a test battery of short-wavelength automated perimetry and pattern electroretinography.

Authors:  Andreas U Bayer; Klaus-Peter Maag; Carl Erb
Journal:  Ophthalmology       Date:  2002-07       Impact factor: 12.079

Review 9.  Update on the pattern electroretinogram in glaucoma.

Authors:  Michael Bach; Michael B Hoffmann
Journal:  Optom Vis Sci       Date:  2008-06       Impact factor: 1.973

10.  Testing for glaucoma with frequency-doubling perimetry in normals, ocular hypertensives, and glaucoma patients.

Authors:  Folkert K Horn; Nina Wakili; Anselm M Jünemann; Matthias Korth
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2002-07-05       Impact factor: 3.117

View more
  2 in total

1.  [Importance of perimetric differential diagnostics in patients with primary open-angle glaucoma].

Authors:  C Erb; K Göbel
Journal:  Ophthalmologe       Date:  2013-02       Impact factor: 1.059

2.  Influence of ACPA-positive rheumatoid arthritis on visual field testing in patients with arterial hypertension: A comparative cross-sectional study.

Authors:  Jascha Wendelstein; Barbara Fuchs; Sarah Schlittgen; Robert Zielke; Jeanette Brünner; Matthias Bolz; Rielke Alten; Carl Erb
Journal:  Ophthalmic Physiol Opt       Date:  2021-06-02       Impact factor: 3.117

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.